Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boston settles with J&J over heart patents for $716m

This article was originally published in Clinica

Executive Summary

Long-time cardiology adversaries Boston Scientific and Johnson & Johnson have settled 14 patent infringement lawsuits relating to the use and design of coronary stents and its related devices. Boston will pay J&J $716m to dismiss the lawsuits, which include the Palmaz-NIR patent case, in North America, Germany, France, Italy and Belgium. The funds will come from Boston's existing reserve for the Palmaz-NIR suit and from existing cash in hand. The settlement resolves most of the litigation between the two companies, although there are at least three lawsuits that are still active, according to The Wall Street Journal. The agreement comes four months after Medtronic said it will pay J&J $270m to settle their respective stent patent dispute (www.clinica.co.uk, May 11 2009).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT044407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel